Ablynx announced that Boehringer Ingelheim has selected, as part of their strategic alliance, a second Nanobody candidate for pre-clinical development, which triggered a €5 million milestone payment to Ablynx.  more »

Impax Pharmaceuticals has licensed from AstraZeneca the exclusive United States (U.S.) commercial rights to Zomig (zolmitriptan) tablet, orally disintegrating tablet, and nasal spray formulations.  more »

The Drugs for Neglected Diseases initiative and Abbott have signed a four-year joint research and non-exclusive licensing agreement to undertake research on new treatments for several of the world’s most neglected tropical diseases, including Chagas disease, helminth infections, leishmaniasis and sleeping sickness.  more »

WuXi PharmaTech and ShangPharma are both attractive M&A targets, according to a Bloomberg News article. Both China CROs have higher profit margins than their US peers, and both are growing faster than US CROs. Nevertheless, their PE ratios are lower, making them value propositions for their US competitors.  more »

AngioDynamics has entered into a definitive agreement to acquire privately-held Navilyst Medical in a transaction valued at $372 million based on yesterday’s closing stock price of $14.20.  more »

McKesson Corporation announced that it has signed a definitive agreement to purchase Drug Trading Company Limited the independent banner business of Katz Group.  more »

ConforMIS announced that it has raised $89 million in a Series E round of funding, with additional funds beyond this amount committed upon meeting certain milestones.  more »

Steve Holtzman got his first taste of corporate venture capital back in 1987, when he raised money from SR One, back when it was part of an old company known as Smith, Kline & French more »

Verastem announced the pricing of its initial public offering of 5,500,000 shares of its common stock at $10.00 per share, before underwriting discounts and commissions.

All of the shares in the offering are being sold by Verastem.  more »

WuXi PharmaTech and ShangPharma are both attractive M&A targets, according to a Bloomberg News article. Both China CROs have higher profit margins than their US peers, and both are growing faster than US CROs. Nevertheless, their PE ratios are lower, making them value propositions for their US competitors.  more »

GlaxoSmithKline, Eli Lilly and Pfizer are among about half a dozen companies interested in buying a stake in Mustafa Nevzat Ilac Sanayii AS in a deal that may value the Turkish drugmaker at $1 billion, three people with knowledge of the situation said.  more »

GlaxoSmithKline Plc (GSK), the U.K.’s largest drugmaker, is seeking an acquisition in Turkey as it struggles to become profitable in the country, Hurriyet said, citing the company’s emerging markets president more »